Review





Similar Products

mouse aspartate aminotransferase, ast genlisa elisa  (Krishgen Biosystems)
93
Krishgen Biosystems mouse aspartate aminotransferase, ast genlisa elisa
Mouse Aspartate Aminotransferase, Ast Genlisa Elisa, supplied by Krishgen Biosystems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspartic/Mouse+Aspartate+aminotransferase%2C+AST+GENLISA+ELISA/custom%40klm0329%4010%2E1186%2Fs41110-026-00524-w
Average 93 stars, based on 1 article reviews
mouse aspartate aminotransferase, ast genlisa elisa - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
glast glutamate aspartate transporter  (Miltenyi Biotec)
96
Miltenyi Biotec glast glutamate aspartate transporter
Selection of tissue‐specific surface targets and validation markers. Graphic representation of the tissue and cell type explored in this study. Nervous system EVs have been investigated targeting surface markers specific to neurons, astrocytes and microglia cells. The EV subpopulation from neurons was enriched targeting the growth‐associated protein 43 (GAP43) and neuroligin 3 (NLGN3) as surface markers, while the validation was assessed by measuring the amount of synaptophysin protein (SYP). EVs released from astrocytes and microglia cells were immunoprecipitated using antibodies towards the glutamate aspartate <t>transporter</t> <t>(GLAST,</t> also known as Excitatory amino acid transporter 1‐EAAT1) and the transmembrane protein 119 (TMEM119) respectively and measuring glial fibrillary acidic protein (GFAP) protein for astrocyte EVs, human allograft inflammatory factor 1 (AIF1) and purinergic receptor P2Y12 (P2RY12) for microglia EVs. The human type I cell 56‐kDa protein (HT1‐56) and/or the advanced glycosylation end‐product specific receptor (AGER) were targeted to enrich EVs release from the Alveolar Type 1 lung cells (AT1 cells). The validation was performed by measuring the protein level of human aquaporin 5 (AQP5) and human napsin‐A (NAPSA). Liver EVs released from hepatocytes have been immunocaptured targeting glucose transporter 2 (GLUT2) and/or the asialoglycoprotein receptor 1 (ASGR1), validating the protein level of ASGR1 and cytochrome P450 family 2 subfamily E member 1 (CYP2E1). EVs released from the placenta tissue, specifically from trophoblast cells, have been targeted using placental alkaline phosphatase (PLAP) as surface marker, and measuring the level of cytochrome P450 family 19 subfamily A member 1 (CYP19A1) as validation marker.
Glast Glutamate Aspartate Transporter, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspartic/GLAST+(ACSA-1)+Antibody%2C+anti-human%2Fmouse%2Frat/pmc13364545-2-0-5
Average 96 stars, based on 1 article reviews
glast glutamate aspartate transporter - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
aspartate aminotransferase  (Nanjing Jiancheng Bioengineering Research Institute Co Ltd)
86
Nanjing Jiancheng Bioengineering Research Institute Co Ltd aspartate aminotransferase
Selection of tissue‐specific surface targets and validation markers. Graphic representation of the tissue and cell type explored in this study. Nervous system EVs have been investigated targeting surface markers specific to neurons, astrocytes and microglia cells. The EV subpopulation from neurons was enriched targeting the growth‐associated protein 43 (GAP43) and neuroligin 3 (NLGN3) as surface markers, while the validation was assessed by measuring the amount of synaptophysin protein (SYP). EVs released from astrocytes and microglia cells were immunoprecipitated using antibodies towards the glutamate aspartate <t>transporter</t> <t>(GLAST,</t> also known as Excitatory amino acid transporter 1‐EAAT1) and the transmembrane protein 119 (TMEM119) respectively and measuring glial fibrillary acidic protein (GFAP) protein for astrocyte EVs, human allograft inflammatory factor 1 (AIF1) and purinergic receptor P2Y12 (P2RY12) for microglia EVs. The human type I cell 56‐kDa protein (HT1‐56) and/or the advanced glycosylation end‐product specific receptor (AGER) were targeted to enrich EVs release from the Alveolar Type 1 lung cells (AT1 cells). The validation was performed by measuring the protein level of human aquaporin 5 (AQP5) and human napsin‐A (NAPSA). Liver EVs released from hepatocytes have been immunocaptured targeting glucose transporter 2 (GLUT2) and/or the asialoglycoprotein receptor 1 (ASGR1), validating the protein level of ASGR1 and cytochrome P450 family 2 subfamily E member 1 (CYP2E1). EVs released from the placenta tissue, specifically from trophoblast cells, have been targeted using placental alkaline phosphatase (PLAP) as surface marker, and measuring the level of cytochrome P450 family 19 subfamily A member 1 (CYP19A1) as validation marker.
Aspartate Aminotransferase, supplied by Nanjing Jiancheng Bioengineering Research Institute Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspartic/aminotransferase+aspartate/pmc13129436-51-30-38
Average 86 stars, based on 1 article reviews
aspartate aminotransferase - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
mouse ast (aspartate aminotransferase) elisa kit  (Guangzhou JET Bio-Filtration)
94
Guangzhou JET Bio-Filtration mouse ast (aspartate aminotransferase) elisa kit
Selection of tissue‐specific surface targets and validation markers. Graphic representation of the tissue and cell type explored in this study. Nervous system EVs have been investigated targeting surface markers specific to neurons, astrocytes and microglia cells. The EV subpopulation from neurons was enriched targeting the growth‐associated protein 43 (GAP43) and neuroligin 3 (NLGN3) as surface markers, while the validation was assessed by measuring the amount of synaptophysin protein (SYP). EVs released from astrocytes and microglia cells were immunoprecipitated using antibodies towards the glutamate aspartate <t>transporter</t> <t>(GLAST,</t> also known as Excitatory amino acid transporter 1‐EAAT1) and the transmembrane protein 119 (TMEM119) respectively and measuring glial fibrillary acidic protein (GFAP) protein for astrocyte EVs, human allograft inflammatory factor 1 (AIF1) and purinergic receptor P2Y12 (P2RY12) for microglia EVs. The human type I cell 56‐kDa protein (HT1‐56) and/or the advanced glycosylation end‐product specific receptor (AGER) were targeted to enrich EVs release from the Alveolar Type 1 lung cells (AT1 cells). The validation was performed by measuring the protein level of human aquaporin 5 (AQP5) and human napsin‐A (NAPSA). Liver EVs released from hepatocytes have been immunocaptured targeting glucose transporter 2 (GLUT2) and/or the asialoglycoprotein receptor 1 (ASGR1), validating the protein level of ASGR1 and cytochrome P450 family 2 subfamily E member 1 (CYP2E1). EVs released from the placenta tissue, specifically from trophoblast cells, have been targeted using placental alkaline phosphatase (PLAP) as surface marker, and measuring the level of cytochrome P450 family 19 subfamily A member 1 (CYP19A1) as validation marker.
Mouse Ast (Aspartate Aminotransferase) Elisa Kit, supplied by Guangzhou JET Bio-Filtration, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspartic/Mouse+AST+(Aspartate+Aminotransferase)+ELISA+Kit/custom%40e-el-m0160%4042364047
Average 94 stars, based on 1 article reviews
mouse ast (aspartate aminotransferase) elisa kit - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
aspartate aminotransferase (ast/got) activity assay kit  (Guangzhou JET Bio-Filtration)
94
Guangzhou JET Bio-Filtration aspartate aminotransferase (ast/got) activity assay kit
Selection of tissue‐specific surface targets and validation markers. Graphic representation of the tissue and cell type explored in this study. Nervous system EVs have been investigated targeting surface markers specific to neurons, astrocytes and microglia cells. The EV subpopulation from neurons was enriched targeting the growth‐associated protein 43 (GAP43) and neuroligin 3 (NLGN3) as surface markers, while the validation was assessed by measuring the amount of synaptophysin protein (SYP). EVs released from astrocytes and microglia cells were immunoprecipitated using antibodies towards the glutamate aspartate <t>transporter</t> <t>(GLAST,</t> also known as Excitatory amino acid transporter 1‐EAAT1) and the transmembrane protein 119 (TMEM119) respectively and measuring glial fibrillary acidic protein (GFAP) protein for astrocyte EVs, human allograft inflammatory factor 1 (AIF1) and purinergic receptor P2Y12 (P2RY12) for microglia EVs. The human type I cell 56‐kDa protein (HT1‐56) and/or the advanced glycosylation end‐product specific receptor (AGER) were targeted to enrich EVs release from the Alveolar Type 1 lung cells (AT1 cells). The validation was performed by measuring the protein level of human aquaporin 5 (AQP5) and human napsin‐A (NAPSA). Liver EVs released from hepatocytes have been immunocaptured targeting glucose transporter 2 (GLUT2) and/or the asialoglycoprotein receptor 1 (ASGR1), validating the protein level of ASGR1 and cytochrome P450 family 2 subfamily E member 1 (CYP2E1). EVs released from the placenta tissue, specifically from trophoblast cells, have been targeted using placental alkaline phosphatase (PLAP) as surface marker, and measuring the level of cytochrome P450 family 19 subfamily A member 1 (CYP19A1) as validation marker.
Aspartate Aminotransferase (Ast/Got) Activity Assay Kit, supplied by Guangzhou JET Bio-Filtration, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspartic/Aspartate+Aminotransferase+(AST%2FGOT)+Activity+Assay+Kit/custom%40e-bc-k236-s%4042365698
Average 94 stars, based on 1 article reviews
aspartate aminotransferase (ast/got) activity assay kit - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
aspartate aminotransferase assay kit  (Nanjing Jiancheng Bioengineering Research Institute Co Ltd)
86
Nanjing Jiancheng Bioengineering Research Institute Co Ltd aspartate aminotransferase assay kit
Selection of tissue‐specific surface targets and validation markers. Graphic representation of the tissue and cell type explored in this study. Nervous system EVs have been investigated targeting surface markers specific to neurons, astrocytes and microglia cells. The EV subpopulation from neurons was enriched targeting the growth‐associated protein 43 (GAP43) and neuroligin 3 (NLGN3) as surface markers, while the validation was assessed by measuring the amount of synaptophysin protein (SYP). EVs released from astrocytes and microglia cells were immunoprecipitated using antibodies towards the glutamate aspartate <t>transporter</t> <t>(GLAST,</t> also known as Excitatory amino acid transporter 1‐EAAT1) and the transmembrane protein 119 (TMEM119) respectively and measuring glial fibrillary acidic protein (GFAP) protein for astrocyte EVs, human allograft inflammatory factor 1 (AIF1) and purinergic receptor P2Y12 (P2RY12) for microglia EVs. The human type I cell 56‐kDa protein (HT1‐56) and/or the advanced glycosylation end‐product specific receptor (AGER) were targeted to enrich EVs release from the Alveolar Type 1 lung cells (AT1 cells). The validation was performed by measuring the protein level of human aquaporin 5 (AQP5) and human napsin‐A (NAPSA). Liver EVs released from hepatocytes have been immunocaptured targeting glucose transporter 2 (GLUT2) and/or the asialoglycoprotein receptor 1 (ASGR1), validating the protein level of ASGR1 and cytochrome P450 family 2 subfamily E member 1 (CYP2E1). EVs released from the placenta tissue, specifically from trophoblast cells, have been targeted using placental alkaline phosphatase (PLAP) as surface marker, and measuring the level of cytochrome P450 family 19 subfamily A member 1 (CYP19A1) as validation marker.
Aspartate Aminotransferase Assay Kit, supplied by Nanjing Jiancheng Bioengineering Research Institute Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspartic/aminotransferase+aspartate/pm42319089-79-27-32
Average 86 stars, based on 1 article reviews
aspartate aminotransferase assay kit - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
insulin aspart  (Novo Nordisk)
86
Novo Nordisk insulin aspart
Selection of tissue‐specific surface targets and validation markers. Graphic representation of the tissue and cell type explored in this study. Nervous system EVs have been investigated targeting surface markers specific to neurons, astrocytes and microglia cells. The EV subpopulation from neurons was enriched targeting the growth‐associated protein 43 (GAP43) and neuroligin 3 (NLGN3) as surface markers, while the validation was assessed by measuring the amount of synaptophysin protein (SYP). EVs released from astrocytes and microglia cells were immunoprecipitated using antibodies towards the glutamate aspartate <t>transporter</t> <t>(GLAST,</t> also known as Excitatory amino acid transporter 1‐EAAT1) and the transmembrane protein 119 (TMEM119) respectively and measuring glial fibrillary acidic protein (GFAP) protein for astrocyte EVs, human allograft inflammatory factor 1 (AIF1) and purinergic receptor P2Y12 (P2RY12) for microglia EVs. The human type I cell 56‐kDa protein (HT1‐56) and/or the advanced glycosylation end‐product specific receptor (AGER) were targeted to enrich EVs release from the Alveolar Type 1 lung cells (AT1 cells). The validation was performed by measuring the protein level of human aquaporin 5 (AQP5) and human napsin‐A (NAPSA). Liver EVs released from hepatocytes have been immunocaptured targeting glucose transporter 2 (GLUT2) and/or the asialoglycoprotein receptor 1 (ASGR1), validating the protein level of ASGR1 and cytochrome P450 family 2 subfamily E member 1 (CYP2E1). EVs released from the placenta tissue, specifically from trophoblast cells, have been targeted using placental alkaline phosphatase (PLAP) as surface marker, and measuring the level of cytochrome P450 family 19 subfamily A member 1 (CYP19A1) as validation marker.
Insulin Aspart, supplied by Novo Nordisk, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspartic/aspart+insulin/pm42297745-44-14-22
Average 86 stars, based on 1 article reviews
insulin aspart - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
aspartate ammonia lyase  (Janssen)
86
Janssen aspartate ammonia lyase
Selection of tissue‐specific surface targets and validation markers. Graphic representation of the tissue and cell type explored in this study. Nervous system EVs have been investigated targeting surface markers specific to neurons, astrocytes and microglia cells. The EV subpopulation from neurons was enriched targeting the growth‐associated protein 43 (GAP43) and neuroligin 3 (NLGN3) as surface markers, while the validation was assessed by measuring the amount of synaptophysin protein (SYP). EVs released from astrocytes and microglia cells were immunoprecipitated using antibodies towards the glutamate aspartate <t>transporter</t> <t>(GLAST,</t> also known as Excitatory amino acid transporter 1‐EAAT1) and the transmembrane protein 119 (TMEM119) respectively and measuring glial fibrillary acidic protein (GFAP) protein for astrocyte EVs, human allograft inflammatory factor 1 (AIF1) and purinergic receptor P2Y12 (P2RY12) for microglia EVs. The human type I cell 56‐kDa protein (HT1‐56) and/or the advanced glycosylation end‐product specific receptor (AGER) were targeted to enrich EVs release from the Alveolar Type 1 lung cells (AT1 cells). The validation was performed by measuring the protein level of human aquaporin 5 (AQP5) and human napsin‐A (NAPSA). Liver EVs released from hepatocytes have been immunocaptured targeting glucose transporter 2 (GLUT2) and/or the asialoglycoprotein receptor 1 (ASGR1), validating the protein level of ASGR1 and cytochrome P450 family 2 subfamily E member 1 (CYP2E1). EVs released from the placenta tissue, specifically from trophoblast cells, have been targeted using placental alkaline phosphatase (PLAP) as surface marker, and measuring the level of cytochrome P450 family 19 subfamily A member 1 (CYP19A1) as validation marker.
Aspartate Ammonia Lyase, supplied by Janssen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/aspartic/ammonia+aspartate+lyase/pm42275544-524-20-7
Average 86 stars, based on 1 article reviews
aspartate ammonia lyase - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


Selection of tissue‐specific surface targets and validation markers. Graphic representation of the tissue and cell type explored in this study. Nervous system EVs have been investigated targeting surface markers specific to neurons, astrocytes and microglia cells. The EV subpopulation from neurons was enriched targeting the growth‐associated protein 43 (GAP43) and neuroligin 3 (NLGN3) as surface markers, while the validation was assessed by measuring the amount of synaptophysin protein (SYP). EVs released from astrocytes and microglia cells were immunoprecipitated using antibodies towards the glutamate aspartate transporter (GLAST, also known as Excitatory amino acid transporter 1‐EAAT1) and the transmembrane protein 119 (TMEM119) respectively and measuring glial fibrillary acidic protein (GFAP) protein for astrocyte EVs, human allograft inflammatory factor 1 (AIF1) and purinergic receptor P2Y12 (P2RY12) for microglia EVs. The human type I cell 56‐kDa protein (HT1‐56) and/or the advanced glycosylation end‐product specific receptor (AGER) were targeted to enrich EVs release from the Alveolar Type 1 lung cells (AT1 cells). The validation was performed by measuring the protein level of human aquaporin 5 (AQP5) and human napsin‐A (NAPSA). Liver EVs released from hepatocytes have been immunocaptured targeting glucose transporter 2 (GLUT2) and/or the asialoglycoprotein receptor 1 (ASGR1), validating the protein level of ASGR1 and cytochrome P450 family 2 subfamily E member 1 (CYP2E1). EVs released from the placenta tissue, specifically from trophoblast cells, have been targeted using placental alkaline phosphatase (PLAP) as surface marker, and measuring the level of cytochrome P450 family 19 subfamily A member 1 (CYP19A1) as validation marker.

Journal: Journal of Extracellular Biology

Article Title: Immunoaffinity‐Based Protocol to Enrich Nervous System Cell‐, Lung Alveolar Cell‐, and Hepatocyte‐Derived Extracellular Vesicles From Human Plasma

doi: 10.1002/jex2.70171

Figure Lengend Snippet: Selection of tissue‐specific surface targets and validation markers. Graphic representation of the tissue and cell type explored in this study. Nervous system EVs have been investigated targeting surface markers specific to neurons, astrocytes and microglia cells. The EV subpopulation from neurons was enriched targeting the growth‐associated protein 43 (GAP43) and neuroligin 3 (NLGN3) as surface markers, while the validation was assessed by measuring the amount of synaptophysin protein (SYP). EVs released from astrocytes and microglia cells were immunoprecipitated using antibodies towards the glutamate aspartate transporter (GLAST, also known as Excitatory amino acid transporter 1‐EAAT1) and the transmembrane protein 119 (TMEM119) respectively and measuring glial fibrillary acidic protein (GFAP) protein for astrocyte EVs, human allograft inflammatory factor 1 (AIF1) and purinergic receptor P2Y12 (P2RY12) for microglia EVs. The human type I cell 56‐kDa protein (HT1‐56) and/or the advanced glycosylation end‐product specific receptor (AGER) were targeted to enrich EVs release from the Alveolar Type 1 lung cells (AT1 cells). The validation was performed by measuring the protein level of human aquaporin 5 (AQP5) and human napsin‐A (NAPSA). Liver EVs released from hepatocytes have been immunocaptured targeting glucose transporter 2 (GLUT2) and/or the asialoglycoprotein receptor 1 (ASGR1), validating the protein level of ASGR1 and cytochrome P450 family 2 subfamily E member 1 (CYP2E1). EVs released from the placenta tissue, specifically from trophoblast cells, have been targeted using placental alkaline phosphatase (PLAP) as surface marker, and measuring the level of cytochrome P450 family 19 subfamily A member 1 (CYP19A1) as validation marker.

Article Snippet: GLAST Glutamate Aspartate Transporter , Miltenyi Biotec (Bergisch Gladbach, Germany) , 130‐118‐984 , Monoclonal , 5.0 , Astrocyte , NS.

Techniques: Selection, Biomarker Discovery, Immunoprecipitation, Glycoproteomics, Marker

TS‐EV validation by immunoassay. Bar plots show EV subpopulations validated for tissue‐specific markers, comparing the fractions obtained by IP to the isotype control and the total EV. Data are reported as relative average concentration (ng/mL) ± SEM. (A) GAP43 + || NLGN3 + EVs from neurons; (B) GLAST + EVs from astrocytes; (C, D) TMEM119 + EVs from microglia cells; (E–H) HT1‐56 + EVs, (F–I) AGER + EVs and (G–L) HT1‐56 + || AGER + EVs from alveolar type I lung cells; (M–Q) GLUT2 + EVs, (N–R) ASGR1 + EVs, (O–S) GLUT2 + || ASGR1 + EVs (positive for at least one marker) and (P–T) GLUT2 + /ASGR1 + (‘double‐positive’) EVs from hepatocytes.

Journal: Journal of Extracellular Biology

Article Title: Immunoaffinity‐Based Protocol to Enrich Nervous System Cell‐, Lung Alveolar Cell‐, and Hepatocyte‐Derived Extracellular Vesicles From Human Plasma

doi: 10.1002/jex2.70171

Figure Lengend Snippet: TS‐EV validation by immunoassay. Bar plots show EV subpopulations validated for tissue‐specific markers, comparing the fractions obtained by IP to the isotype control and the total EV. Data are reported as relative average concentration (ng/mL) ± SEM. (A) GAP43 + || NLGN3 + EVs from neurons; (B) GLAST + EVs from astrocytes; (C, D) TMEM119 + EVs from microglia cells; (E–H) HT1‐56 + EVs, (F–I) AGER + EVs and (G–L) HT1‐56 + || AGER + EVs from alveolar type I lung cells; (M–Q) GLUT2 + EVs, (N–R) ASGR1 + EVs, (O–S) GLUT2 + || ASGR1 + EVs (positive for at least one marker) and (P–T) GLUT2 + /ASGR1 + (‘double‐positive’) EVs from hepatocytes.

Article Snippet: GLAST Glutamate Aspartate Transporter , Miltenyi Biotec (Bergisch Gladbach, Germany) , 130‐118‐984 , Monoclonal , 5.0 , Astrocyte , NS.

Techniques: Biomarker Discovery, Control, Concentration Assay, Marker